Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Benzopyrronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 14/20 | 0.85 |
| ▸ | CHRM2 known ✓ | P08172 | 10/20 | 0.85 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.71 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.71 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | HRH1 | P35367 | 2/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzopyrronium SCHEMBL2111041 | 0.99 | CHRM3 (0.85) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Parapenzolate SCHEMBL636125 | 0.93 | CHRM3 (0.74) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL17008166 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL15575855 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL15575981 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL147471 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL99030 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Parapenzolate SCHEMBL14547205 | 0.92 | CHRM3 (0.73) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL3401786 | 0.91 | CHRM3 (0.97) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 | |
| Mepenzolate SCHEMBL19411950 | 0.91 | CHRM3 (0.97) | CHRM3CHRM2SLC22A1KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4088717-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4035668-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | Chase Pharmaceuticals Corporation (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | CHASE PHARMACEUTICALS CORP (US) | 2019-03-28 | — | — | US | disclosed |
| WO-2019033068-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | WO | disclosed |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM3 4299/4885CHRM2 4524/4885CHRM1 4575/4885 |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 5/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 5/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CHRM3 3926/4885CHRM2 4279/4885CHRM1 4394/4885 |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHRM2, CHRM1, CHRM4 | CHRM3 5/4885CHRM2 1/4885CHRM1 2/4885 |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | CHRM3 32/4885CHRM2 46/4885CHRM1 60/4885 |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | ACHE, BCHE, CHAT | CHRM3 18/4885CHRM2 11/4885CHRM1 25/4885 |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | CHRM3 299/4885CHRM2 251/4885CHRM1 369/4885 |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | CHRM3 299/4885CHRM2 251/4885CHRM1 369/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM3 4193/4885CHRM2 4525/4885CHRM1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.